While these findings may not offer novel perspectives for developing new therapeutic approaches, an ACS risk assessment combining IL-6 and ceramide (d18:1/16:0) presents a unique tool for aiding clinical implementation and decision-making in patients suspected of having atherosclerosis. This evidence concerns the gene IL6 and atherosclerosis.